May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Excimer laser treatment of topographic central islands in combination with mitomycine–C results in a hyperopic shift
Author Affiliations & Notes
  • F.A. G. J. Eggink
    Refractive surgery unit, The Rotterdam Eye Hospital, Rotterdam, The Netherlands
  • J.J. M. Willemse Assink
    Ophthalmology, Erasmus University, Medical Center, Rotterdam, The Netherlands
  • G. van Rij
    Ophthalmology, Erasmus University, Medical Center, Rotterdam, The Netherlands
  • Footnotes
    Commercial Relationships  F.A.G.J. Eggink, None; J.J.M. Willemse Assink, None; G. van Rij, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 158. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F.A. G. J. Eggink, J.J. M. Willemse Assink, G. van Rij; Excimer laser treatment of topographic central islands in combination with mitomycine–C results in a hyperopic shift . Invest. Ophthalmol. Vis. Sci. 2004;45(13):158.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the efficacy of using central reablation in combination with prophylactic application of 0.02% mitomycine–C, for the treatment of topographic central islands in combination with haze, following photorefractive keratectomy (PRK). Methods: Seven patient eyes with mean preoperative refractive spherical equivalent of –5.0 D, developed central islands in combination with haze which persisted more than 4 months. All patients lost more than 2 lines of BSCVA (mean 5 lines) and complained of visual disturbance. Reablation was tailored to each eye using the Technolas 217 excimer laser, based on the diameter and power of the topographic central island using the Munnerlyn formula. After ablation, the stromal surface was treated with a 0.02% mitomycine–C solution during 20 to 30 seconds using a soaked merocel sponge. The follow up of all patients was at least 6 months after the treatment with mitomycine–C. Results: Six months after the procedure, the visual loss was reduced to one line of the preoperative BSCVA level in six eyes (85%). One eye lost 3 lines of preoperative BSCVA. Mean postoperative refractive equivalent was + 1.3 D. Conclusions: Repeated laser ablation combined with the application of topical mitomycine–C to remove central islands and haze is effective. However it results in a hyperopic shift of + 1.3 D.

Keywords: refractive surgery: complications • refractive surgery: other technologies • refractive surgery: optical quality 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×